FDA OCE with EMA to host a Conversations on Cancer public panel discussion Oct. 19
The FDA Oncology Center of Excellence (OCE) in conjunction with the European Medicines Agency (EMA) will host a Conversations on Cancer public panel discussion October 19, 2023, addressing the experience of living with metastatic breast cancer. The panel will feature speakers with a range of perspectives on breast cancer and, for the first time, will be an international collaboration with our colleagues at the EMA with the hope of highlighting the day-to-day, year-to-year experience of patients living with metastatic breast cancer (https://www.surveymonkey.com/r/SGF5FCPExternal Link Disclaimer).
“The FDA’s OncologybCenter of Excellence is excited to join with the EMA for this important discussion on cancer survivorship and the varied global experiences of people living with metastatic breast cancer,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Oncologic Diseases in the FDA’s Center for Drug Evaluation and Research. “Cancer survivorship continues to be an issue of growing importance that we see highlighted through science-led projects like Cancer Moonshot in the U.S. and the EU beating cancer plan in EU. Given our new collaboration with the EMA, we hope to learn from any commonalities as well as distinctions amongst patients and providers in U.S. and Europe.”
FDA has the meeting registration.